Purchase Order 75N95023P00418
Award Date
7/12/23
Potential Completion Date
9/10/23
Potential Value
$10K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Cellecta, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Mountain View, CA 94043, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $24,000 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Cellecta, Inc. Cellecta is a for-profit manufacturer of specialty genetic screening products and services used in medical research and drug discovery. The contract does not have a small business set-aside designation. Cellecta frequently partners as the prime contractor to provide CRISPR, RNAi, and other genomic...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $20,130.00 firm-fixed-price purchase order to Cellecta, Inc. (doing business as Cellecta Inc.), a for-profit organization and manufacturer of goods. The award is for the delivery of a human genome-wide CRISPR-Cas9 dual-single guide RNA (sgRNA) library (virus). This contract is not set aside for any type of small business. Cellecta has previously provided a...
This is a $96,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genetic research tools. The award supports NCATS' RNAi screening facility by enabling the development of flexible functional genomics platforms that offer complementary and orthogonal CRISPR screens to NIH intramural investigators. The contract does not...
This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Cellecta, Inc., a for-profit manufacturer of genetic research tools and services. The $13,500.00 contract is for the delivery of Cellecta's proprietary lentiviral packaging products to support biomedical research. The contract does not have a small business set-aside designation. Cellecta has consistently secured federal contracts and grants, primarily from the National...
This federal contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genomic research products and services. The $299,952 firm-fixed price contract is for "GENETIC ANALYSIS OF CTCS AT THE SINGLE-CELL LEVEL" and does not have a set-aside designation. Cellecta specializes in providing advanced genomic technologies, including CRISPR, RNAi, and other tools, to support biomedical research...
This federal contract award to Cellecta, Inc., a for-profit manufacturer of genetic research tools, was issued by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH). The $16,305 firm fixed-price purchase order is for the delivery of a pooled single guide RNA (sgRNA) CRISPR-Cas9 library, which will support biomedical research initiatives. The contract did not have a small business set-aside designation. Cellecta has been a consistent...
Stemcell Technologies Inc. was awarded a firm fixed price purchase order valued at twenty-four thousand eight hundred eighty dollars and sixty-two cents ($24,880.62) by the Department of Health and Human Services' National Institutes of Health National Institute on Aging on September 17, 2019. The award has no set-aside designation. Stemcell Technologies Inc. is a subsidiary of Stemcell Technologies, a Canadian company that develops cell culture media, separation systems, and other life sciences...
Nanocellect Biomedical Inc., a for-profit biotechnology company, was awarded a $115,390.00 firm fixed price purchase order from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Human Genome Research Institute. The award was for the provision of a NanoCellect WOLF Cell Sorter and N1 Cell Dispenser, which aligns with the original solicitation for these products. No set-aside designation was used. Nanocellect Biomedical has a history of providing...
The Department of Health and Human Services National Institutes of Health (NIH) awarded a firm-fixed-price purchase order contract to Nanocellect Biomedical Inc., a for-profit organization, for a microfluidic cell sorter. The total potential value of the contract is $149,680.00, with a completion date of August 31, 2022. The contract does not have a set-aside designation. Nanocellect Biomedical is a biotechnology company that provides automated cell analysis, sorting, and dispensing equipment,...
Nanocellect Biomedical Inc. has been awarded a $95,120 firm fixed price purchase order by the National Heart, Lung and Blood Institute of the National Institutes of Health within the Department of Health and Human Services. Under this contract, Nanocellect Biomedical will identify actionable molecular pathways of acute rejection treatment failure in lung transplants to support the Institute's research efforts to improve outcomes for lung transplant patients. Performance will occur in San...